Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals.

Journal Article (Journal Article;Review)

The HCV viral life cycle provides targets for drug development at virtually every step, and many new drugs aimed at these targets are currently being developed. Clinical practice takes a major step forward this year with the arrival of telaprevir and boceprevir, which will be added to the current standard of care of pegIFNα/RBV. Patients will need to be monitored closely and counseled extensively, and clinicians will need to learn the new response-guided therapy algorithms with these therapies. Although there remains work to be done in the field of HCV, these therapies will allow many more patients the opportunity to eradicate HCV infection.

Full Text

Duke Authors

Cited Authors

  • Jazwinski, AB; Muir, AJ

Published Date

  • September 2011

Published In

Volume / Issue

  • 40 / 3

Start / End Page

  • 481 - 494

PubMed ID

  • 21893269

Pubmed Central ID

  • PMC5144163

Electronic International Standard Serial Number (EISSN)

  • 1558-1942

Digital Object Identifier (DOI)

  • 10.1016/j.gtc.2011.06.005


  • eng

Conference Location

  • United States